Your browser is no longer supported. Please, upgrade your browser.
Tempest Therapeutics, Inc.
Index- P/E- EPS (ttm)-24.99 Insider Own1.10% Shs Outstand0.93M Perf Week-15.74%
Market Cap88.86M Forward P/E- EPS next Y-4.61 Insider Trans0.00% Shs Float- Perf Month-18.35%
Income-26.10M PEG- EPS next Q-1.11 Inst Own27.40% Short Float- Perf Quarter-24.86%
Sales- P/S- EPS this Y40.60% Inst Trans- Short Ratio0.73 Perf Half Y-19.51%
Book/sh51.99 P/B0.23 EPS next Y35.50% ROA-52.40% Target Price37.00 Perf Year-55.51%
Cash/sh- P/C- EPS next 5Y- ROE-72.00% 52W Range10.39 - 41.55 Perf YTD-62.99%
Dividend- P/FCF- EPS past 5Y45.60% ROI- 52W High-71.41% Beta0.40
Dividend %- Quick Ratio7.20 Sales past 5Y- Gross Margin- 52W Low14.40% ATR0.88
Employees12 Current Ratio7.20 Sales Q/Q- Oper. Margin- RSI (14)28.54 Volatility6.20% 5.71%
OptionableYes Debt/Eq0.00 EPS Q/Q9.50% Profit Margin- Rel Volume0.21 Prev Close12.15
ShortableYes LT Debt/Eq0.31 Earnings- Payout- Avg Volume111.70K Price11.88
Recom2.00 SMA20-17.92% SMA50-17.68% SMA200-41.60% Volume23,029 Change-2.22%
Oct-01-21 08:00AM  
Sep-20-21 08:00AM  
Sep-13-21 08:00AM  
Sep-09-21 04:01PM  
Aug-12-21 04:01PM  
Aug-09-21 08:00AM  
Jul-09-21 08:00AM  
Jul-01-21 04:00PM  
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha, and is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company is headquartered in South San Francisco, California.